Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

Employee Rating

4.7More
TypePublic
HQRedwood City, US
Founded2010
Size (employees)139 (est)+10%
Websitecoherus.com
Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Coherus BioSciences

Dennis M. Lanfear

Dennis M. Lanfear

President, CEO & Chairman
Alan Herman

Alan Herman

Chief Scientific Officer
Jean-Frederic Viret

Jean-Frederic Viret

CFO
Peter Watler

Peter Watler

CTO
Vince Anicetti

Vince Anicetti

COO
Michael Fleming

Michael Fleming

Evp, Corporate and Competitive Strategy & President, Intekrin Therapeutics
Show more

Coherus BioSciences Office Locations

Coherus BioSciences has an office in Redwood City
Redwood City, US (HQ)
600 333 Twin Dolphin Dr
Show all (1)
Report incorrect company information

Coherus BioSciences Financials and Metrics

Coherus BioSciences Revenue

Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017
USD

Net income (Q3, 2018)

(58.8m)

EBIT (Q3, 2018)

(57.0m)

Market capitalization (17-Jan-2019)

755.8m

Closing stock price (17-Jan-2019)

11.1

Cash (30-Sep-2018)

101.2m
Coherus BioSciences's current market capitalization is $755.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.1m30.0m190.1m1.6m

Revenue growth, %

(3%)533%

General and administrative expense

17.6m36.0m51.6m71.3m

R&D expense

78.2m213.1m254.4m162.4m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

12.4m14.1m

General and administrative expense

4.0m6.1m8.8m10.2m11.4m11.3m13.6m18.8m23.5m14.0m16.6m18.4m25.4m

R&D expense

18.5m36.5m56.9m68.2m65.3m65.5m64.6m53.8m34.5m42.6m25.5m26.5m31.6m

Operating expense total

22.5m42.6m65.8m78.4m76.7m76.8m78.2m72.6m58.0m56.6m42.0m44.9m57.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

150.4m158.2m124.9m126.9m

Inventories

1.9m

Current Assets

179.1m197.4m161.5m145.5m

PP&E

4.5m10.5m10.8m12.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m135.6m82.0m130.0m101.2m

Current Assets

118.9m143.9m239.6m189.3m211.6m236.8m177.3m208.3m153.3m171.6m112.2m172.8m130.3m

PP&E

3.7m5.1m6.3m8.7m10.3m9.9m10.7m14.9m14.5m13.8m11.9m11.2m6.8m

Goodwill

943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(87.2m)(223.9m)(127.8m)(238.3m)

Depreciation and Amortization

674.0k3.0m3.4m

Accounts Payable

3.6m(5.0m)(3.8m)

Cash From Operating Activities

(23.9m)(252.5m)(200.3m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(7.9m)(40.8m)(99.9m)(171.4m)(65.5m)(135.7m)(51.8m)(74.8m)(130.2m)(189.2m)(44.3m)(88.0m)(146.8m)

Depreciation and Amortization

632.0k1.3m717.0k1.4m2.2m865.0k1.7m2.5m922.0k1.8m2.6m

Accounts Payable

4.4m10.9m7.1m19.1m(6.8m)(7.4m)(1.6m)(7.3m)(3.8m)(9.2m)(1.1m)(2.3m)(7.8m)

Cash From Operating Activities

(53.9m)(113.6m)(76.3m)(103.7m)(165.7m)(73.3m)(128.9m)(170.4m)(33.6m)(69.1m)(111.9m)
USDY, 2018

Financial Leverage

11.4 x
Show all financial metrics
Report incorrect company information

Coherus BioSciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Coherus BioSciences News and Updates

Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners.

Coherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer

REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019.

Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco.

Global Behcet Disease Treatment Market Insights by Major Applications, and Top Business Players: AbbVie Inc, Celgene Corp, Coherus BioSciences Inc, Novartis AG, R Pharm, Cell Medica Ltd and other

The Behcet Disease Treatment Market report focuses on the global Behcet Disease Treatment Industry status, future forecast, growth opportunity, key market and key players. Posted via Industry Today. Follow us on Twitter @IndustryToday

Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference

REDWOOD CITY, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse Healthcare Conference being held in Scottsdale, Arizona on Thursday, November 15 at 9:45 am MST.

Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

REDWOOD CITY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim bi…
Show more
Report incorrect company information

Coherus BioSciences Company Life and Culture

Report incorrect company information

Coherus BioSciences Frequently Asked Questions

  • When was Coherus BioSciences founded?

    Coherus BioSciences was founded in 2010.

  • Who are Coherus BioSciences key executives?

    Coherus BioSciences's key executives are Dennis M. Lanfear, Alan Herman and Jean-Frederic Viret.

  • How many employees does Coherus BioSciences have?

    Coherus BioSciences has 139 employees.

  • What is Coherus BioSciences revenue?

    Latest Coherus BioSciences annual revenue is $1.6 m.

  • What is Coherus BioSciences revenue per employee?

    Latest Coherus BioSciences revenue per employee is $11.2 k.

  • Who are Coherus BioSciences competitors?

    Competitors of Coherus BioSciences include Sojournix, Tiburio Therapeutics and Casma Therapeutics.

  • Where is Coherus BioSciences headquarters?

    Coherus BioSciences headquarters is located at 600 333 Twin Dolphin Dr, Redwood City.

  • Where are Coherus BioSciences offices?

    Coherus BioSciences has an office in Redwood City.

  • How many offices does Coherus BioSciences have?

    Coherus BioSciences has 1 office.